New Study Links Osteoporosis Drugs to Atypical Bone Fractures

Posted on May 29, 2012

A new study done by Swiss researchers suggests that popular osteoporosis drugs (bisphosphonates) may pose a risk for unusual fractures. The study looked at 477 patients who were 50 and older and who had been hospitalized with subtrochanteric or femoral shaft fractures at the University Hospitals of Geneva.

Out of the 477 patients with fractures, thirty-nine patients with atypical fractures were identified. Researchers found that of the patients who had atypical fractures, 82 percent had been treated with bisphosphonates.

This is the latest in a growing list of studies over the years that have suggested long-term bisphosphonate use may be linked to unusual femur fractures. In some cases, the thighbone can snap like a piece of chalk with little or no warning. Some patients have reported that the only warning sign they had before a fracture was an ache in their thigh.

Bisphosphonates, such as Actonel, Boniva, Fosamax, and Reclast have been prescribed for years as drugs that can prevent spine and hip fractures in those with weakened bones.

Besides unusual fracture problems, bisphosphonates have also been linked to a rare jaw disorder called “death of the jaw” (osteonecrosis) which is marked by pain, swelling, infection, and exposed bone.

The U.S. Food and Drug Administration (FDA) recently warned that those using this class of drugs might need to be reevaluated after three to five years of use.

It is a drug manufacturers duty to assure that a drug they are distributing is safe and effective. If you believe that a drug you have been taking has injured you, a personal injury attorney in Sarasota County at Farah & Farah can evaluate your claim to see if you have a case. We’re a quick and easy phone call away at (800) 533-3555. We are here to see that your legal rights are protected.

  • This field is for validation purposes and should be left unchanged.